JP Morgan Maintains Overweight Rating and Raises Price Target for Seaport Therapeutics
JP Morgan has maintained its 'Overweight' rating on Seaport Therapeutics, Inc. and increased its price target from $40 to $41.
Stocks · News reference
Seaport Therapeutics Reports Third Quarter 2026 Financial Results and Clinical Progress
Seaport Therapeutics announced its third-quarter 2026 financial results, reporting a net loss of $26.4 million and highlighting key clinical milestones for its Glyph platform candidates.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- fiscal.ai
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
8-K filing — Seaport Therapeutics, Inc. (SPTX)
Filed: 2026-11-02 AccNo: 0001193125-26-442625 Size: 339 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Seaport Therapeutics to Present at Stifel 2026 Healthcare Conference
Seaport Therapeutics, Inc. announced its participation in the upcoming Stifel 2026 Healthcare Conference, where management will present and conduct investor meetings.
This Entegris Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday
Analysts initiated coverage on VYLR, IMTX, ENTG, SLGL and SPTX, assigning Neutral, Buy or Overweight ratings and price targets.
Canaccord Genuity Initiates Coverage On Seaport Therapeutics with Buy Rating, Announces Price Target of $28
Canaccord Genuity analyst Sumant Kulkarni initiates coverage on Seaport Therapeutics (NASDAQ:SPTX) with a Buy rating and announces Price Target of $28.
Seaport Therapeutics To Present Phase 1 Clinical Data For GlyphAgo At The European College Of Neuropsychopharmacology Congress, October 10-13